Printer Friendly

Adimab, Inc. Expands Scientific Advisory Board With Dr. Sachdev Sidhu.

LEBANON, N.H. -- Adimab, Inc. today announces the addition of Dr. Sachdev Sidhu to its scientific advisory board. Dr. Sidhu recently joined the faculty in the Banting and Best Department of Medical Research at the University of Toronto. Professor Sidhu returns to academia after a distinguished career at Genentech where he led the development of the company's phage display technology.

"At Genentech Dr. Sidhu made significant contributions and established himself as a recognized thought leader in the area of semi-synthetic antibody library design," said Dr. Tillman Gerngross, Adimab Chief Executive Officer and Co-founder. "He brings a wealth of experience in commercial antibody discovery and we are excited to have him join the board."

Dr. Dane Wittrup, the Chairman of Adimab's Scientific Advisory Board, added, "Dr. Sidhu is intimately familiar with conventional antibody discovery technologies and has been on the cutting edge of the field for many years. In particular, he has made major contributions to understanding the functional importance of the amino acid composition of antibody binding sites. His insight will be highly valued."

"I'm very excited to join Adimab's scientific advisory board," remarked Dr. Sidhu, "the company is pushing the envelope on what is possible in therapeutic antibody engineering, and I look forward to working with the team."

Dr. Sidhu joins the current scientific advisory board consisting of: Prof. Stanley Fields, a Howard Hughes Medical Investigator at the University of Washington, Prof. Jim Marks of the National Academy of Medicine and the University of California, San Francisco, Prof. Bruce Tidor of the Massachusetts Institute of Technology, and Dr. Dane Wittrup, Chairman and Co-founder of Adimab and Professor of Engineering at the Massachusetts Institute of Technology.

About Adimab, Inc.

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology. For more information, visit
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 28, 2008
Previous Article:Emerging Opportunities in Outsourced F&A Services Market Spurred Impressive 22% Annual FAO Growth, Says Everest's Annual Report.
Next Article:Tungle Meeting Coordinator Now Available for the 5.4 Million iPhone(TM) Users.

Related Articles
CytoTherapeutics acquires stem cell product pipeline
DermTech International.
Dr. McClellan named by President Bush to head FDA; Senate approval expected.
HTS Biosystems' FLEXCHIP Kinetic Analysis System Enables New Research Directions for University of Utah and Genentech Studies.
Adimab Announces Scientific Advisory Board Members.
Joanne Sun, Ph.D. Joins Adimab, Inc. as Director of Protein Analytics and High Throughput Purification.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters